Eltrombopag (Revlan) main indications and treatment of thrombocytopenia

Eltrombopag is an oral small molecule thrombopoietin receptor agonist (TPO-RA) that can bind to the thrombopoietin receptor (c-Mpl) to promote megakaryocyte proliferation and differentiation, thereby increasing platelet production. The drug was originally developed to address the problem of patients with chronic immune thrombocytopenia (ITP) who do not respond well to traditional treatments such as glucocorticoids, immunoglobulins or splenectomy. Its unique oral form and good tolerance make eltrombopag one of the important drugs in the clinical treatment of thrombocytopenia caused by various causes.

In terms of main indications, eltrombopag is mainly used for three types of patients: the first type is adults and children with chronic immune thrombocytopenia (ITP), especially those who have failed other treatments; the second type is patients with chronic hepatitis C (< span>HCV)-related thrombocytopenia, used to maintain safe platelet levels during antiviral treatment; the third category is patients with severe aplastic anemia (SAA), especially cases that are unresponsive to immunosuppressive therapy. These indications have been rigorously clinically verified, and eltrombopag has shown significant effects in improving platelet counts and reducing the risk of bleeding.

In the treatment of thrombocytopenia, eltrombopag stimulates the production of megakaryocytes in the bone marrow and promotes the release of platelets, thereby increasing the number of platelets in peripheral blood. Clinical studies have shown that after taking eltrombopag, most patients with ITP can achieve platelet loss within 11 to 2 weeks. The count can increase significantly and remain within a safe range (usually ≥50×10⁹/L). At the same time, it can effectively reduce the occurrence of bleeding events and improve patients' quality of life. Unlike traditional immunosuppressive treatments, eltrombopag does not directly suppress the immune system, so the risk of infection is relatively low with long-term use.

It is worth noting that although eltrombopag can effectively control thrombocytopenia, it is not a radical drug. Some patients' platelet levels may drop again after stopping the drug, so an individualized treatment and monitoring plan needs to be developed under the guidance of a doctor. During use, platelet count, liver function and serum bilirubin levels should be checked regularly to avoid excessive elevation leading to the risk of thrombosis. Through scientific and standardized long-term management, eltrombopag can help patients with thrombocytopenia maintain platelet levels within a safe range, significantly reduce the risk of bleeding and improve quality of life.

Reference materials:https://www.drugs.com/